Adamas Pharmaceuticals Inc (ADMS) Return on Equity ROE from the third quarter 2021 to third quarter 2020 and annually, average high and low, overall ranking from Sep 30 2021 to Sep 30 2020 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Adamas Pharmaceuticals Inc  (NASDAQ: ADMS)

Adamas Pharmaceuticals Inc's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Adamas Pharmaceuticals Inc in the third quarter 2021?
Due to the lack of equity, it was not possible to calculate Adamas Pharmaceuticals Inc's return on equity (ROE) in its third quarter 2021

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Sep 30 2021)
III. Quarter		 (Jun 30 2021)
II. Quarter		 (Mar 31 2021)
I. Quarter		 (Dec 31 2020)
IV. Quarter		 (Sep 30 2020)
III. Quarter
Y / Y Equity Change - - - - -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -63 -55 -53 -57 -62
Return On Equity (TTM) - - - - -
ADMS's Total Ranking # # # # #
Equity (TTM) in Millions -22 -4 6 -50 -35
Seq. Equity Change - - - - -
Seq. Net Income Change - - - - -

Back to ADMS Management Effectiveness >> ADMS's 5 Years Annual ROE >> Compare ADMS ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Equity Statistics
High Average Low
0 %
0 %
0 %
 





ADMS Annual Return On Equity (Dec 31 2020)
2020		 (Dec 31 2019)
2019		 (Dec 31 2018)
2018		 (Dec 31 2017)
2017		 (Dec 31 2016)
2016
Total Equity in Millions -50 -1 90 66 132
Y / Y Equity Change - - 35.93 % -49.97 % 13.77 %
Net Income in Millions -57 -105 -131 -89 -60
Y / Y Net Income Change - - - - -
Return On Equity - - -145.74 % -135.33 % -45.44 %

Back to ADMS Management Effectiveness >> ADMS's 5 Years Annual ROE >> Compare ADMS ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
ADMS's' Return on Equity at Yahoo Finance
ADMS's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for ADMS's Competitors
Subscribers only: Roe for Adamas Pharmaceuticals Inc's Suppliers
Subscribers only: Return On Equity for ADMS's Customers




Companies with similar Return On Equity at Sep 30 2021, within Healthcare Sector ROE
Biovie Inc   926.59 %
Aceragen Inc   354.42 %
Cryo cell International Inc   353.07 %
Hca Healthcare Inc   329.74 %
Mettler toledo International Inc   329.11 %
Waters Corporation  270.76 %
Halozyme Therapeutics Inc   263.91 %
Tivity Health Inc   231.08 %
Ironwood Pharmaceuticals inc   167.74 %
Tenet Healthcare Corp  134.79 %
Vyne Therapeutics Inc   128.61 %
Strata Critical Medical Inc   122.85 %
Moderna Inc   121.61 %
Molecular Templates Inc   120.06 %
Carisma Therapeutics Inc   117.54 %
Silo Pharma Inc  116.87 %
Agios Pharmaceuticals Inc   110.22 %
Idexx Laboratories Inc  106.63 %
Eli Lilly And Company  86.74 %
Davita Inc   82.66 %
Adicet Bio Inc   79.44 %
Orgenesis Inc   77.05 %
Ovid Therapeutics Inc   75.88 %
Uniqure N v   75.59 %
Innoviva Inc   72.73 %

Date modified: 2026-09-08T15:10:25+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.